New drug aims to outsmart resistant prostate cancer
Disease control
Recruiting now
This early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink …
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC